Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Evotec AG O.N. (EVTG)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
14.100 +0.450    +3.30%
06:53:05 - Delayed Data. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  DE0005664809 
S/N:  566480
  • Volume: 6,100
  • Bid/Ask: 14.100 / 14.200
  • Day's Range: 13.950 - 14.100
Evotec AG 14.100 +0.450 +3.30%

ETR:EVTG Financials

 
A brief overview of the ETR:EVTG financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Evotec AG over time.

Evotec SE reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was EUR 196.28 million compared to EUR 173.88 million a year ago. Net loss was EUR 38.96 million compared to EUR 47.28 million a year ago. Basic loss per share from continuing operations was EUR 0.22 compared to EUR 0.27 a year ago. Diluted loss per share from continuing operations was EUR 0.22 compared to EUR 0.27 a year ago.For the nine months, sales was EUR 580.11 million compared to EUR 510.76 million a year ago. Net loss was EUR 67.78 million compared to EUR 148.45 million a year ago. Basic loss per share from continuing operations was EUR 0.38 compared to EUR 0.84 a year ago. Diluted loss per share from continuing operations was EUR 0.38 compared to EUR 0.84 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

EVTG Income Statement

Gross margin TTM 26.78%
Operating margin TTM 0.77%
Net Profit margin TTM -11.57%
Return on Investment TTM 0.29%
 Total Revenue  Net Income
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Revenue 196.28 170.28 191.92 240.69
Gross Profit 37.82 46.32 49.78 82.46
Operating Income -12.18 -36.29 10.32 37.16
Net Income -38.96 -14.93 -14.41 -27.2

EVTG Balance Sheet

Quick Ratio MRQ 1.78
Current Ratio MRQ 2.16
LT Debt to Equity MRQ 38.96%
Total Debt to Equity MRQ 51.61%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Assets 2254.51 2301.22 2257.25
Total Liabilities 1113.69 1126.93 1070.06
Total Equity 1140.82 1174.29 1187.18 1187.18

EVTG Cash Flow Statement

Cash Flow/Share TTM -0.1
Revenue/Share TTM 4.64
Operating Cash Flow  4.78%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 20.76 -2.79 -2.79 -33.53
Cash From Investing Activities -15.76 14.4 14.4 19.21
Cash From Financing Activities 43.37 5.24 5.24 -1.96
Net Change in Cash 39.62 22.3 22.3 -48.76
* In Millions of EUR (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

EVTG Comments

Write your thoughts about Evotec AG
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Bill Boulton
Bill Boulton Feb 19, 2021 10:01AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
To be fair the stock has had large (lazy) short positions for many months and the US DoD deal is not new news. Also, the sceince of  monoclonal antibodies is still not proven. That said, as a pipeline of royalties begin to come through adding to top lines my outlook remains  €50 target in 3 years.
Reply
0 0
Report
Daimon van Buren
Daimon van Buren Jan 27, 2021 4:00AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
lol railing Melvin Capital left and right
Reply
0 0
Report
In Sight
Insight Jan 27, 2021 4:00AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Doesnt have anything to do with that here but rather the us military filing in a huge order at evotec for anti bodies against covid (over the next 7 years)
Reply
1 0
Report
Bill Boulton
Bill Boulton Mar 04, 2019 10:11AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
155171057981821.jpg
The valuation is very much a "sum of the parts" not a not a future valuation. The potentials from a series of bolt on company purchases and ongoing strategic alliances will see a valuation of €10Bn within the next 5 years. What is not priced in to the current valuation is the vision of the management  and shear quality of the science.. . Volatility is an issue so hold on to your hat !!. . Still not convinced ? Where else could you have got 50%+ return on stocks for the past three years ??
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email